| identifier: | 1812630 |
| description: |
epitope description:alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer
antigen name:lipooligosaccharide
host organism:Mus musculus C3H/He
antibody name:CGM3
|
| aggregation: |
instance of dataset
|
| availability: |
available
|
| primaryPublications: |
18184663 |
| authorizations: |
registration not required
|
| accessURL: |
http://www.iedb.org/reference/1012585 |
| landingPage: |
http://www.iedb.org/assay/1812630 |
| type: |
Literature
|
| publicationVenue: |
Brain
|
| dates: |
2008
|
| study type: | b cell assays |
| subject species: | Campylobacter jejuni |
| fullName: |
Susan K Halstead
Femke M P Zitman
Peter D Humphreys
Kay Greenshields
Jan J Verschuuren
Bart C Jacobs
Russell P Rother
Jaap J Plomp
Hugh J Willison
|
| method: |
immuno staining
|
| name: |
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
|
| description: |
The epitope-specific mAb bound to mouse motor nerve terminals and disrupted their axonal integrity. Treatment of the cells with normal human serum showed complement binding, but the addition of another mAb, eculizumab directed against the complement protein C5, blocked complement deposition and protected axonal integrity..
|
| name: |
iedb
|
| homePage: |
http://www.iedb.org |